Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease caused by the fungus Histoplasma capsulatum. It primarily affects the lungs but can also occur as a disseminated disease that affects additional organs. The acute respiratory disease has symptoms similar to those of a cold or flu and it usually resolves without treatment in healthy individuals. The disseminated form is generally fatal if untreated.
Biomarker and diagnostic research for histoplasmosis has been reported in the published literature.
No approved treatments are currently available for histoplasmosis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for histoplasmosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for histoplasmosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily sponsored by academic and government institutions.
324 publications have been identified in PubMed for histoplasmosis. Research spans Case Report / Case Series (37%), Epidemiology / Natural History (21%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 121 | 37% |
Data assembled from 5 of 12 sources · Last updated Nov 3, 2026, 4:16 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Liposomal amphotericin B | Liposomal amphotericin B | Fujisawa USA, Inc. | 1996 | — | Designated |
Gene therapy approaches for histoplasmosis have been reported in the published literature.
1 trial found
Disease patterns and progression |
69 |
21% |
Research summaries | 54 | 17% |
Testing and diagnosis research | 31 | 10% |
Laboratory research | 30 | 9% |
Clinical study results | 12 | 4% |
Other research | 5 | 2% |
New treatment approaches | 2 | 1% |
Como K (2026). [PMID: 41771251](https://pubmed.ncbi.nlm.nih.gov/41771251/). *Am J Vet Res*. [Diagnostic / Biomarker]
Nassif ND (2026). [PMID: 42047461](https://pubmed.ncbi.nlm.nih.gov/42047461/). *Future Microbiol*. [Epidemiology / Natural History]
Behjatnia H (2026). [PMID: 41578627](https://pubmed.ncbi.nlm.nih.gov/41578627/). *Am J Case Rep*. [Case Report / Case Series]
Van Praet JT (2026). [PMID: 42139918](https://pubmed.ncbi.nlm.nih.gov/42139918/). *Diagn Microbiol Infect Dis*. [Case Report / Case Series]
Couto AP (2026). [PMID: 42207106](https://pubmed.ncbi.nlm.nih.gov/42207106/). *Arq Bras Oftalmol*. [Other]
Asokan S (2026). [PMID: 41564537](https://pubmed.ncbi.nlm.nih.gov/41564537/). *Diagn Microbiol Infect Dis*. [Review / Meta-Analysis]
Kitano T (2026). [PMID: 41370984](https://pubmed.ncbi.nlm.nih.gov/41370984/). *J Infect Public Health*. [Basic Science / Preclinical]
Mota MAL (2026). [PMID: 41452335](https://pubmed.ncbi.nlm.nih.gov/41452335/). *Med Mycol*. [Epidemiology / Natural History]
Woods G (2026). [PMID: 42049583](https://pubmed.ncbi.nlm.nih.gov/42049583/). *Vet Clin North Am Small Anim Pract*. [Review / Meta-Analysis]
Kao TW (2026). [PMID: 41612525](https://pubmed.ncbi.nlm.nih.gov/41612525/). *Emerging infectious diseases*. [Epidemiology / Natural History]
AI-curated news mentioning histoplasmosis
Updated Oct 13, 2026
A recent case report highlights the diagnostic value of skin biopsy in identifying fatal histoplasmosis-associated hemophagocytic lymphohistiocytosis. This study contributes to the understanding of diagnostic approaches for this rare condition.
A case study highlights gastric involvement in disseminated histoplasmosis in an immunocompetent patient from a nonendemic region. This finding may expand understanding of histoplasmosis presentations and inform clinical approaches.
A case report highlights secondary hemophagocytic lymphohistiocytosis in an immunocompetent adult, emphasizing the need to differentiate between sarcoidosis and histoplasmosis. This research contributes to the understanding of complex presentations in rare diseases.